Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 10709397

[Urticaria].

B Schnyder·A Helbling
View original source ↗Export metadata ↓

Abstract

Urticaria may affect as many as 25% of all people at some time during their lives. The hallmark of urticaria are transitory and completely reversible wheals (intracutaneous oedema). There are multiple causes of urticaria. It has various clinical expressions. Corresponding to the time course it is possible to differentiate between acute, acute relapsing and chronic urticaria. Acute and acute relapsing urticaria is often caused by an allergy or "pseudoallergy". Causal factors of chronic urticaria are usually elusive and therefore only a symptomatic treatment is possible. H1 antihistamines with a low potential for sedation are the most important first-line treatment.

Explore related subjects

Diagnosis, DifferentialHistamine H1 AntagonistsHumansHypersensitivityUrticariaEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Schnyder, A Helbling. 2000-01-27. [Urticaria].. https://pubmed.ncbi.nlm.nih.gov/10709397/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities.

Primary effusion lymphoma (PEL) is a B-cell neoplasm characterized by infection of the tumor clone by human herpesvirus type-8/Kaposi's sarcoma-associated herpesvirus (HHV-8/KSHV) and by liquid growth in fluid-filled body spaces. During its entire clinical course, the lymphoma tends to remain localized to the serous body cavities with no formation of solid tumor masses. The epidemiology of PEL points to a close link with underlying immunodeficiency of the host, as most cases develop in individuals severely immunocompromised because of preexisting acquired immunodeficiency syndrome. The histogenesis and pathogenesis of PEL have been clarified to a sizeable extent by intensive investigations performed since the disease recognition in 1995. PEL is composed of postgerminal center B cells, which bridge immunoblastic and anaplastic features and typically display a non-B, non-T phenotype consistent with late stages of B-cell differentiation. HHV-8/KSHV is thought to play a major role in PEL pathogenesis via expression of several viral latent genes, which have the potential to affect B-cell growth. Other factors involved in PEL pathogenesis include deregulation of cytokine and growth factor autocrine loops, molecular alterations of the tumor DNA, cell cycle abnormalities, stimulation and selection by antigen, and infection by Epstein-Barr virus, which occurs in 70% of PEL cases. In the years since the disease discovery, the distinctiveness of the biological and clinicopathological features of PEL has prompted its recognition as an independent lymphoma category by the World Health Organization classification system of hematologic neoplasms.

Diagnosis, Differential↗